RB SFCE 2009 : Adjuvant treatment in extensive unilateral retinoblastoma primary enucleated

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514844-10-00

Acronym

IC 2009-04

Enrollment

195

Registered

2024-08-14

Start date

2010-03-18

Completion date

Unknown

Last updated

2025-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinoblastoma

Brief summary

Rate of extra ocular relapses

Detailed description

Evaluate long term and acute toxicities of adjuvant chemotherapy and orbital irradiation., Number of patient with secondary bilateralisation, Evaluate the different histopathological risk factors frequency., To determine tumors genomic., Evaluate sensitivity of MRI in detecting extra ocular extension.

Interventions

DRUGONCOVIN 1 mg

DRUGsolution injectable

DRUGCARBOPLATINE TEVA 10 mg/ml

DRUGsolution pour perfusion

DRUGENDOXAN 1000 mg

DRUGpoudre pour solution injectable

DRUGETOPOSIDE TEVA 20 mg/ml

DRUGsolution à diluer pour perfusion

DRUGTEPADINA 15 mg powder for concentrate for solution for infusion

DRUGTHIOTEPA GENOPHARM 15 mg

DRUGlyophilisat pour usage parentéral

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Rate of extra ocular relapses	—

Secondary

Measure	Time frame
Evaluate long term and acute toxicities of adjuvant chemotherapy and orbital irradiation., Number of patient with secondary bilateralisation, Evaluate the different histopathological risk factors frequency., To determine tumors genomic., Evaluate sensitivity of MRI in detecting extra ocular extension.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026